- Report
- May 2024
- 140 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- November 2024
- 73 Pages
Global
From €3323EUR$3,495USD£2,791GBP
- Report
- December 2024
- 49 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- September 2024
- 80 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2022
United States
From €1844EUR$1,940USD£1,549GBP
- Report
- August 2022
Global
From €751EUR$790USD£631GBP
- Report
- August 2021
Global
From €3793EUR$3,990USD£3,187GBP
- Report
- August 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2022
- 230 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 39 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Glomerulonephritis is a type of kidney disorder that affects the glomeruli, the tiny filters in the kidneys that help remove waste from the blood. Treatment for glomerulonephritis typically involves medications to reduce inflammation, control blood pressure, and reduce proteinuria. Common drugs used to treat glomerulonephritis include ACE inhibitors, angiotensin receptor blockers, diuretics, and immunosuppressants.
Liver and kidney disorders drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, and glomerulonephritis. These drugs can help reduce inflammation, control blood pressure, and reduce proteinuria. Common drugs used to treat liver and kidney disorders include antivirals, antifibrotics, and immunosuppressants.
Some companies in the glomerulonephritis drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more